

Amendments to the Specification

Amend the Replacement copy of the English translation of the specification filed January 27, 2006, as follows.

At page 2, amend the last paragraph as follows:

Our studies disclose that Sequoyitol is able to significantly alleviate hyperglycemia in of diabetes models, inhibit the decomposition of hepatic glycogen and the absorption of glucose, reduce the blood fat level, improve the metabolism of free radicals, and protect the β cells of the pancreatic island; Sequoyitol does not reduce the normal blood-sugar level of mice; and it has an extremely low toxicity. Thus, Sequoyitol can be used for the prevention and treatment of diabetes and complications thereof, for the prevention and treatment of metabolic disorder-associated diseases (such as hyperlipemia, fatty liver, obesity, etc.), and to improve ~~for improvement of~~ the metabolism of free radicals.

On page 4, amend the first paragraph as follows:

The present invention further provides a use of said Sequoyitol in the manufacture of a medicament for the treatment of diabetes. Said medicament is able to significantly alleviate the hyperglycemia of diabetes, inhibit the decomposition of hepatic glycogen and the absorption of glucose, reduce the blood fat level, improve the metabolism of free radicals, and protect the β cells of the pancreatic island; and, Sequoyitol has an extremely low toxicity. Said medicament can be used for

prevention and treatment of diabetes and complications in terms of diabetic cardiovascular and cerebrovascular[[]], and glycometabolic disorder-associated diseases, for the improvement of improve the metabolism of free radicals, and for the prevention and treatment of type-II diabetes and complications in terms of diabetic cardiovascular and cerebrovascular.

At page 28, amend the last paragraph as follows:

All mice did not die, and had a better health status, glossy ~~gloss~~ fur, bright eyes, and a good range ~~rang~~ of motion. The mice were executed after 7 days, and their main organs were free of abnormality under macroscopic observation. Since Sequoyitol has a very low toxicity or even is nontoxic, the LD₅₀ of mice orally administered ~~by oral administration~~ of Sequoyitol was not determined.

At page 29, amend the second full paragraph as follows:

All mice did not die, and had a better health status, glossy ~~gloss~~ fur, bright eyes, and a good range ~~rang~~ of motion. The mice were executed after 14 days, and their main organs were free of abnormality under macroscopic observation.

At page 30, amend the first paragraph as follows:

All mice had a better health status, glossy ~~gloss~~ fur, bright eyes, and a good range ~~rang~~ of motion. The mice were executed after 14 days, and their main organs were free of abnormality under macroscopic observation. Since Sequoyitol has a very low toxicity or

even is nontoxic, the LD₅₀ of mice intravenously administered ~~by intravenous administration of Sequoyitol~~ was not determined.